Updated: January 25, 2026
What Is Ganciclovir? Uses, Dosage, and What You Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Ganciclovir (Cytovene, Zirgan) is an antiviral used to treat CMV infections in AIDS and transplant patients. Here's everything you need to know in 2026.
Ganciclovir is an antiviral medication that has been used in medicine since the late 1980s. It plays a critical role in protecting some of the most vulnerable patients — people living with HIV/AIDS, organ transplant recipients, and others whose immune systems are severely weakened — from a virus called cytomegalovirus (CMV) that can cause blindness, pneumonia, and other life-threatening complications.
This guide explains what ganciclovir is, who it is used for, what forms it comes in, how it is dosed, and what every patient needs to know before starting treatment.
What Is Ganciclovir?
Ganciclovir is a synthetic antiviral drug in the class of nucleoside analogue antivirals. It was patented in 1980 and received its first FDA approval in 1988-1989. It belongs to the same family as acyclovir but is more potent against CMV (cytomegalovirus).
Ganciclovir is sold under two main brand names in the United States:
Cytovene-IV: The intravenous (IV) formulation, available as a 500 mg lyophilized powder in a single-dose vial. Generic forms are available.
Zirgan: The ophthalmic gel formulation (0.15%, 5g tube), made by Bausch & Lomb. Brand-name only — no generic is currently available.
What Is Ganciclovir Used For?
Ganciclovir has two distinct FDA-approved applications:
Treatment of CMV retinitis (IV form): CMV retinitis is an eye infection caused by cytomegalovirus that can lead to permanent blindness. It primarily affects people with AIDS whose immune system (CD4 count) has fallen dangerously low. Ganciclovir IV is one of the primary treatments to control this condition.
Prevention of CMV disease after organ transplant (IV form): Transplant recipients take immunosuppressive medications to prevent organ rejection, which leaves them vulnerable to CMV. Ganciclovir IV is used to prevent CMV disease in kidney, heart, liver, and other organ transplant recipients who are at high risk.
Treatment of herpetic keratitis (ophthalmic gel): Zirgan is used to treat acute herpetic keratitis — a herpes simplex virus infection of the cornea that causes painful dendritic ulcers. It can be used in adults and children aged 2 years and older.
What Does Ganciclovir NOT Do?
Ganciclovir controls CMV but does not cure it. The virus can still be in your body after treatment, and CMV retinitis can progress even during therapy. Regular ophthalmology follow-ups are required for patients with CMV retinitis. Ganciclovir also does not work against bacterial infections, COVID-19, or influenza.
Dosage and How It's Given
Ganciclovir IV is given by a healthcare professional — never as a home injection. The standard dosing regimen for CMV retinitis follows two phases:
Induction phase: 5 mg/kg given as a 1-hour IV infusion every 12 hours for 14-21 days. Doses are adjusted for kidney function.
Maintenance phase: 5 mg/kg IV once daily for 7 days per week, or 6 mg/kg once daily for 5 days per week. After stable IV therapy, many patients transition to oral valganciclovir.
For transplant CMV prophylaxis, the IV induction is typically shorter (7-14 days), followed by transition to oral valganciclovir.
For Zirgan ophthalmic gel: Apply 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the dendritic ulcer heals. After healing, continue 1 drop 3 times per day for 7 more days.
Who Should NOT Take Ganciclovir?
People with a known allergy to ganciclovir or valganciclovir
Pregnant women (risk of birth defects — avoid unless benefits clearly outweigh risks)
Patients with absolute neutrophil count below 500 cells/mcL or platelet count below 25,000 cells/mcL (unless no alternative exists)
Is Ganciclovir a Controlled Substance?
No. Ganciclovir is not a DEA-scheduled controlled substance. It does not require a special prescription form, and there are no limits on refills other than standard prescription requirements. However, due to its serious side effects and specialized use, it is managed exclusively by specialists and requires close medical supervision.
For a deeper look at how ganciclovir fights CMV, read our guide on how ganciclovir works.
Having trouble filling your ganciclovir prescription? medfinder calls pharmacies near you to find which ones have it in stock.
Frequently Asked Questions
Ganciclovir IV (Cytovene-IV) is FDA-approved for two uses: (1) treatment of CMV retinitis in immunocompromised adults including those with AIDS, and (2) prevention of CMV disease in organ transplant recipients at high risk for CMV infection. Ganciclovir ophthalmic gel (Zirgan) is FDA-approved for treatment of acute herpetic keratitis (herpes simplex eye infection) in adults and children aged 2 and older.
Ganciclovir is given intravenously (IV), while valganciclovir (Valcyte) is an oral tablet that is converted into ganciclovir in the body. They work the same way. Valganciclovir is preferred for outpatient use because it can be taken by mouth. Most patients on long-term therapy transition from IV ganciclovir to oral valganciclovir once they are clinically stable.
CMV retinitis treatment begins with an induction phase of 14-21 days of IV ganciclovir twice daily, followed by an indefinite maintenance phase once daily until immune reconstitution or disease resolution. Patients on effective HIV antiretroviral therapy who achieve immune recovery (CD4 >100 cells/mcL for 3-6 months) may be able to discontinue ganciclovir maintenance with close ophthalmologic follow-up. Treatment duration is always guided by your specialist.
No. Ganciclovir does not cure CMV — it controls viral replication and reduces viral load, slowing disease progression. The virus remains latent in the body. CMV retinitis can still progress during treatment, which is why regular ophthalmology follow-ups are required. Long-term or ongoing treatment is often necessary depending on the patient's immune status.
Ganciclovir IV use in pediatric patients is considered off-label for most indications. The ophthalmic gel (Zirgan) is FDA-approved for children aged 2 years and older for herpetic keratitis. For IV use in children with CMV disease, dosing is based on weight (mg/kg) and is used by pediatric infectious disease and transplant specialists on a case-by-case basis. Always consult a pediatric specialist.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Ganciclovir also looked for:
More about Ganciclovir
34,519 have already found their meds with Medfinder.
Start your search today.





